Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha ® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017

Late-Breaking Repatha Presentations Assess Impact on Peripheral Artery Disease and Heart Attack Patients THOUSAND OAKS, Calif., Nov. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new analyses will be presented from the Repatha® (evolocumab) cardiovascular outcomes study, including analyses investigating the efficacy of Repatha in high-risk patients with peripheral artery disease (PAD) and those who have experienced a prior heart attack. In total, five distinct analyses from the Repatha cardiovascular outcomes study (FOURIER), including two accepted for late-breaker scientific sessions, will be presented at the American Heart Association (AHA) Scientific Sessions 2017 in A...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news